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Introduction: An increased understanding of the genetic pathways involved in renal cell carcinoma has resulted in
the development of various drugs that target relevant signaling cascades for the specific treatment of this disease.
However, no validated predictive markers have been identified to guide the decision whether patients should
receive vascular endothelial growth factor–targeted therapy or mammalian target of rapamycin–targeted therapy.
We present what is, to the best of our knowledge, the first case of renal cell carcinoma in a patient with tuberous
sclerosis complex who was successfully treated with everolimus.
Case presentation: The patient was a 49-year-old Korean woman with tuberous sclerosis complex and recurrent
renal cell carcinoma. The patient was treated with the tyrosine kinase inhibitor sunitinib followed by the mammalian
target of rapamycin inhibitor everolimus. This treatment resulted in a prolonged response and significant clinical
benefit. Notably, everolimus ameliorated the symptoms related not only to renal cell carcinoma but also to tuberous
sclerosis complex.
Conclusion: This case provides a rationale for the use of everolimus as first-line treatment for this specific patient
population in order to target the correct pathway involved in carcinogenesis.
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Tuberous sclerosis complex (TSC) is an autosomal dom-
inant disease that was first described by Bourneville in
1880 [1]. TSC is characterized by hamartomatous lesions
in various organs, such as the skin, retina, kidney, central
nervous system, heart and lungs [1]. TSC arises from gen-
etic alterations in one of two genes: TSC1 (encoding
hamartin) or TSC2 (encoding tuberin). Tumor cells taken
from patients with TSC have been shown to exhibit active
mammalian target of the rapamycin (mTOR) signaling, so
mTOR inhibitors have been identified as potential thera-
peutic agents.
In this report, we describe the case of a patient with
TSC in whom TSC-related symptoms improved and a* Correspondence: khpark@korea.ac.kr
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reproduction in any medium, provided the orpartial response to recurrent renal cell carcinoma (RCC)
was achieved after treatment with the mTOR inhibitor
everolimus. The findings of this case suggest that evero-
limus is an effective and appropriate treatment for pa-
tients with RCC related to TSC.Case presentation
In May 2009, a 49-year-old Korean woman presented with
complaints of fever and left flank pain to our department.
For the previous two decades, she had received regular
medical care for TSC, which had been diagnosed on the
basis of angiomyolipomas (AMLs) in the kidney and fibro-
adenoma on the face (Figure 1A). Her medical history in-
cluded multiple episodes of seizures during infancy with
no subsequent evidence of significant intellectual deficit.
At the age of 40, the patient experienced spontaneous
pneumothorax in her right lung. Chest computed tomog-
raphy (CT) revealed multiple cystic lesions consistent with. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
Figure 1 Clinical features of tuberous sclerosis complex at diagnosis
and after treatment with everolimus. (A) Photograph of the patient’s
facial fibroadenoma. (B) Chest computed tomographic scan of multiple
cystic lesions consistent with lymphangioleiomyomatosis. (C) through (J)
Brain magnetic resonance imaging scans of the patient. (C) Cortical tubers.
(D) Multiple subependymal nodules. (E) Subependymal giant cell
astrocytoma. (F) through (J) Changes after treatment with everolimus.
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systemic evaluations for clinical TSC manifestations re-
vealed several cortical tubers (Figure 1C), multiple sube-
pendymal nodules (Figure 1D), a subependymal giant cell
astrocytoma (SEGA) detected on brain magnetic reson-
ance images (Figure 1E) and retinal hamartomas identifiedduring ophthalmologic examinations. Echocardiography
and endoscopy of the stomach and colon revealed no ab-
normal findings. The aforementioned clinical findings fulfill
the four major diagnostic criteria for a diagnosis of TSC;
thus the diagnosis was confirmed without genomic analysis.
The patient’s family history was unremarkable before her
daughter developed facial angiofibromatosis.
Abdominal sonography was performed to evaluate the
patient’s fever and left flank pain, which revealed a newly
developed mass alongside the AML in the left kidney. Be-
cause radiologic findings indicated the presence of renal
clear cell carcinoma, we performed a radical left nephrec-
tomy and diagnosed RCC on the basis of the histopath-
ology. Pathologic examination revealed three kidney lesions
(Figure 2A) of differing histologies (Figure 2A, arrow B:
AML; arrow C: chromophobe RCC; arrow D: clear cell car-
cinoma). The final tumor node metastasis staging system
classification was T3aN0M0, stage 3, Fuhrman nuclear
grade 2.
In October 2010, approximately 17 months after the
nephrectomy was performed, the patient experienced
fever and left flank pain again. A follow-up CT scan re-
vealed a heterogeneously enhanced mass at the neph-
rectomy site. A biopsy of the soft tissue in the left
subphrenic area allowed us to confirm that this mass
was recurrent RCC, and as a result a multidisciplinary
team decided to administer systemic treatment for this
unresectable and symptomatic disease. The first line of
treatment included daily doses of sunitinib (50mg) for
three months, which resulted in a partial response.
However, recurrent grade 3 thrombocytopenia and sto-
matitis necessitated a 25% dose reduction. Additional
dose reductions were necessary to address recurrent
grade 2 hand-foot syndrome, whole-body folliculitis,
grade 3 diarrhea and grade 2 hypothyroidism.
After 13 months of sunitinib treatment, the lesion re-
grew and the patient’s pain recurred (Figure 3A and 3B).
As second-line treatment, the patient was given oral
everolimus (10mg/day) because it is approved for use in
Korea for patients with recurrent RCC that is resistant
to tyrosine kinase inhibitors (TKIs).
The patient reported complete resolution of pain after
two months of everolimus treatment, and magnetic res-
onance imaging showed a partial response according
to the Response Evaluation Criteria in Solid Tumours
(RECIST 1.1) [2] (Figure 3C). Additionally, the patient’s fa-
cial fibroadenoma had remarkably regressed (Figure 1F),
and, visualized on the follow-up images, the overall renal
mass, including the AML lesion (Figure 3D), had decreased
in size. Other asymptomatic benign lesions, including LAM
(Figure 1G), cortical tubers (Figure 1H), subependymal
nodules (Figure 1I) and SEGA (Figure 1J), had slightly im-
proved. Adverse events were unremarkable with the excep-
tion of asymptomatic pneumonitis, which was observed in
Figure 2 Renal mass shows different pathologies. (A) Photograph showing patient’s renal mass. Arrow B: AML; arrow C: chromophobe RCC;
arrow D: clear cell carcinoma. (B) through (D) Histological tissue specimens showing AML (B), chromophobe renal cell carcinoma (C) clear cell
carcinoma (D). Hematoxylin phloxine saffron stain; original magnification, 200×.
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patient’s treatment had achieved a partial response, and the
patient was in stable condition and continued to receive
treatment.
Discussion
Elucidation of the roles of vascular endothelial growth fac-
tor (VEGF) and mTOR-containing complex 1 (mTORC1)Figure 3 Magnetic resonance images showing the treatment respons
(A) Magnetic resonance imaging was used to produce this image showing
quadrant of abdomen (arrows). (B) Magnetic resonance imaging scan show
partial response to everolimus treatment of renal cell carcinoma close to le
patient’s angiomyolipoma.in RCC has led to evaluation of the use of VEGF and
mTOR inhibitors for the treatment of RCC. Increased un-
derstanding of the phosphatidylinositol 3-kinase (PI3K)/
Akt/mTOR pathway has resulted in the development of
various drugs that specifically target this signaling cascade
[3]. Over the past decade, studies of these targeted agents
have led to revolutionary changes in treatment options for
patients with advanced RCC [1,4-8]. However, no validatede of recurrent renal cell carcinoma and angiomyolipoma.
recurrent renal cell carcinoma at the posterior aspect of left upper
ing angiomyolipoma. (C) Magnetic resonance imaging scan showing
ft diaphragm (arrow). (D) Imaging study showing regression of the
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about which type of therapy should be chosen (VEGF-tar-
geted or mTOR-targeted) [9,10]. Currently, the standard of
care involves selection of the treatment regimen that is
based solely on risk categories reflective of clinical parame-
ters rather than on molecular pathogenesis.
Several known genes are associated with kidney cancer.
Two of these genes, TSC1 and TSC2, are downstream of
AMPK and negatively regulate mTOR in response to cel-
lular energy deficits. Germline mutations in either of these
genes have been identified in patients with TSC, an auto-
somal dominant disorder associated with cutaneous angio-
fibromas, pulmonary lymphangiomyomatosis and renal
tumors [1]. Renal lesions, including AML cysts and RCC,
occur in 60% to 80% of TSC patients with TSC [11,12].
RCC has been reported in 1% to 4% of patients with TSC,
which is a relatively low rate compared to that found in
the whole general population. However, this type of cancer
is typically diagnosed at a younger age in patients with
TSC than in other patients with cancer. In a study group
of patients with TSC, RCC developed at an average age of
28 years [11]. Washecka and Hanna also found in their
review that 43% of TSC patients with RCC had bilateral
disease. Although clear cell RCC is the predominant ma-
lignant histological subtype, TSC-related RCC is unusual
in that it is histologically heterogeneous. Oncocytomas, as
well as clear cell, papillary and chromophobe carcinoma
subtypes, have been reported in patients with TSC [12,13].
Thus, the clinical course and prognosis of RCC associated
with TSC are variable.
In most cases, TSC arises from mutations that inactivate
the TSC1 (hamartin) gene on chromosome 9 or the TSC2
(tuberin) gene on chromosome 16 [14-16]. Either of these
mutations results in constitutive mTOR expression and
impaired tumor suppression in multiple tissues [17,18].
Consequently, the mTOR inhibitor rapamycin was evalu-
ated in clinical, proof-of-principle trials. A total of 13 on-
going trials are being conducted to evaluate the efficacy of
sirolimus, which is topical rapamycin, and everolimus,
which is a rapamycin derivative, for treatment of various
clinical TSC manifestations. Sirolimus treatment for either
LAM of the lung [19] or AML of the kidney [19,20] has
enhanced disease control in a trial setting.
Everolimus is currently licensed to treat patients who
have advanced RCC and disease progression during or
after treatment with VEGF-targeted therapy [6,21]. Before
it was used as an antineoplastic agent, everolimus was ap-
proved as a prophylactic agent for organ rejection in adult
patients receiving allogeneic renal or cardiac transplants.
Everolimus is a selective mTOR inhibitor that specific-
ally targets mTORC1. The kinase activity of mTOR is
activated mainly via the PI3K pathway. As mentioned
above, several laboratory studies and case reports have
suggested that mTOR inhibition leads to the shrinkageor stabilization of renal AML, LAM, facial angiofibroma
and subependymal giant cell astrocytoma [22]. Recently,
everolimus was approved in the European Union and
the United States for the treatment of patients with
SEGA associated with TSC. This approval was based on
the results of a phase II study [23]. No evidence supports
everolimus as first-line therapy over TKIs for patients
with TSC as well as RCC. A case of a pediatric patient
with RCC and TSC-related skin dermatofibrosis treated
with sirolimus has been reported [24], but no data are
available on everolimus as a treatment for RCC in adult
patients with TSC.
Conclusions
In this report, we describe the case of a patient who pre-
sented with RCC as a clinical manifestation of TSC. On
the basis of the presence of TSC, the pathogenic mech-
anism that led to development of RCC in this patient
was clearly defined. Despite our effective use of a TKI in
accordance with treatment guidelines, the patient experi-
enced a multitude of adverse events and her quality of life
was significantly impaired during treatment. In contrast,
second-line treatment with everolimus yielded significant
clinical benefits evidenced by reductions in tumor size and
other TSC manifestations, presumably because of inhib-
ition of the most relevant RCC signaling target. Everoli-
mus conferred these beneficial effects without detrimental
adverse events and therefore did not compromise the pa-
tient’s quality of life. This observation provides a rationale
for the use of everolimus as first-line treatment in this spe-
cific patient population to target the correct pathway in-
volved in carcinogenesis.Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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